USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT

• Main Authors: HIROUCHI, Keita, KIKUCHI, Aya, SATO, Masahito
• Format: Patent
• Language: English; French; German
• Published: 27.08.2025
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

An object of the present invention is to provide an anti-CLDN4/anti-CD 137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treating cancer of a subject, a pharmaceutical composition comprising the bispecific antibody, or a method for treating cancer, including administering an anti-CLDN4/anti-CD137 bispecific antibody in combination with a PD-1 signal inhibitor to a subject. Under a coculture condition of CLDN4 expressing cancer cells and T cells, the use of both an anti-CLDN4/anti-CD137 bispecific antibody and a PD-1 signal inhibitor exhibited a promoting activity on production of interferon-y by a T cell and a cytotoxic action, and exhibited a significant antitumor activity in a CLDN4 expressing cancer cell-transplanted mice, as compared with administration of each alone. From the results, it was shown that a combination of the anti-CLDN4/anti-CD137 bispecific antibody and the PD-1 signal inhibitor is useful for treatment of CLDN4 expressing cancer.